2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2550

Predictive Markers Of Preeclampsia During Pregnancy In Patients With Systemic Erithematosus LUPUS and / Or Antiphospholipid Syndrome
Abstract Number: 2552

Predictive Significance Of ANTI-Prothrombin Antibodies For Second and Third Trimester Obstetric Complications In Patients With Systemic LUPUS Erythematosus and ANTI-Phospholipid Syndrome
Abstract Number: 2245

Predictive Validity Of Low Disease Activity Using Patient Reported Measures On Long-Term Outcomes In Early Rheumatoid Arthritis- Results From Study Of New Onset Rheumatoid Arthritis and Ontario Best Practices Initiative
Abstract Number: 357

Predictive Value Of Anti Cyclic Citrullinated Peptide and Rheumatoid Factor To The Development Of Rheumatoid Arthritis In a Cohort Of Healthy Relatives Of Patients With Rheumatoid Arthritis
Abstract Number: 581

Predictive Value Of The Autoantibody Triad Of Anti-Ro, Anti-Sm and Anti-RNP For The Future Development Of Lupus Nephritis
Abstract Number: 1680

Predictivity Of Serum Biomarkers For Disease Activity In a Prospectively Followed-Up Takayasu Arteritis Cohort: Is Serum Amyloid A Protein Better Than Conventional Acute Phase Markers?
Abstract Number: 996

Predictors and Modeling of Costs in Rheumatoid Arthritis
Abstract Number: 790

Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Abstract Number: 2900

Predictors Of Damage Accrual Over a 2 Year Period In a Large Multi-Racial/Ethnic Lupus Cohort
Abstract Number: 1235

Predictors Of Fracture In Patients With Osteopenia: Data From An Observational Cohort
Abstract Number: 2163

Predictors Of No Improvement In Subjective Health Perception In Newly Diagnosed Rheumatoid Athritis Patients With a Good DAS28 Response At 12 Months In The Dutch Rheumatoid Arthritis Monitoring Tight Control Cohort
Abstract Number: 2005

Predictors Of Outcomes In Tophaceous Gout- Results From a Prospective Cohort At The Veterans Affairs
Abstract Number: 2840

Predictors Of Spinal Mobility Progression In A Multi-ethnic Cohort Of Patients With Ankylosing Spondylitis
Abstract Number: 1224

Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects
Abstract Number: 1370

Prednisone Is a Risk Factor For Pneumocystis Jirovecii Pneumonia In Patients With Rheumatic Diseases: A Case-Control Study With 36 Cases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].